WT
VRTX icon

Wilmington Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Wilmington Trust’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		$360K Sell
3,800
-2,206
-37% -$155K 0.01% 569
2014
Q1 		$424K Buy
+6,006
New +$476K 0.01% 527

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Wilmington Trust's VRTX Position: Q2 2014 in Review

Wilmington Trust reduced its Vertex Pharmaceuticals (VRTX) stake by 37% in Q2 2014, selling an estimated $155K and leaving 3,800 shares worth $360K. The position accounts for 0.01% of the portfolio, ranked #569.

Wilmington Trust first reported a position in VRTX in Q1 2014 and has held it in 2 quarters since. The position peaked at $424K in Q1 2014. 411 funds tracked by Wall St. Rank hold VRTX as of Q2 2014.

  • Wilmington Trust held 3,800 shares of Vertex Pharmaceuticals worth $360K as of Q2 2014.
  • Wilmington Trust sold 2,206 Vertex Pharmaceuticals shares in Q2 2014, an estimated $155K.
  • Vertex Pharmaceuticals made up 0.01% of Wilmington Trust's portfolio in Q2 2014, its #569 holding.
  • Wilmington Trust first reported a position in Vertex Pharmaceuticals in Q1 2014 and has held it in 2 quarters since.
  • Wilmington Trust's Vertex Pharmaceuticals position peaked at $424K in Q1 2014.
  • 411 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2014.

Based on Wilmington Trust's 13F filing for Q2 2014, filed 13 Aug 2014.